Prognostic Value of Serially Estimated Serum Procalcitonin Levels in Traumatic Brain Injury Patients With or Without Extra Cranial Injury on Early In-hospital Mortality: A Longitudinal Observational Study.


Journal

Neurocritical care
ISSN: 1556-0961
Titre abrégé: Neurocrit Care
Pays: United States
ID NLM: 101156086

Informations de publication

Date de publication:
02 2021
Historique:
pubmed: 14 6 2020
medline: 30 9 2021
entrez: 14 6 2020
Statut: ppublish

Résumé

Traumatic brain injury (TBI) is associated with majority of trauma deaths, and objective tools are required to understand the severity of injury. The application of a biomarker like procalcitonin (PCT) in TBI may allow for assessment of severity and thus aid in prognostication and correlation with mortality and outcome. The primary objective is to determine the correlation between PCT concentrations with TBI outcomes (mainly in terms of mortality) at intensive care unit (ICU)/hospital discharge. Secondary objectives are to evaluate correlation with associated extra cranial injuries and complications during hospital stay. In total, 186 TBI patients aged > 18 years with minimum survival for at least 12 h admitted to the ICU at the level 1 trauma center were prospectively included in the study and divided into two groups: TBI with and without extra cranial injuries. All admitted patients were treated according to the standard institutional protocol. The PCT levels were obtained on admission, on day 2, and 5. Clinical, laboratory, diagnostic, and therapeutic data were also collected. Primary mortality is defined as death related to central nervous system (CNS) injury, while secondary mortality defined as death related to sepsis or extracranial cause. Median PCT levels at admission, day 2, and day 5 in TBI patients with extracranial injuries were 3.0, 0.83, and 0.69 ng/ml. In total, primary mortality was observed in 18 (9.7%) patients, while secondary causes were attributable in 20 (12.3%) patients. Regression analysis for primarily CNS cause of mortality showed PCT cutoff level at admission more than 5.5 ng/ml carried sensitivity and specificity of 75%, but for secondary cause (sepsis) of mortality, PCT cutoff values on day 2 > 1.15 ng/ml were derived significant with sensitivity of 70% and specificity of 66%. No significant association of parameters like length of ICU stay, Glasgow outcome scale (GOS), and primary/secondary mortality with the presence of extracranial injuries in TBI patients as compared with TBI alone was noted. This observational study demonstrates the poor correlation between PCT concentrations with outcome at days 1, 2, and 5 post-injury. The predicted relationship between PCT levels and outcome was not confirmed, and that these results do not support the prognostic utility of PCT biomarker in this population for outcome (mortality) assessment in TBI patients with or without extracranial injuries.

Sections du résumé

BACKGROUND
Traumatic brain injury (TBI) is associated with majority of trauma deaths, and objective tools are required to understand the severity of injury. The application of a biomarker like procalcitonin (PCT) in TBI may allow for assessment of severity and thus aid in prognostication and correlation with mortality and outcome.
AIMS
The primary objective is to determine the correlation between PCT concentrations with TBI outcomes (mainly in terms of mortality) at intensive care unit (ICU)/hospital discharge. Secondary objectives are to evaluate correlation with associated extra cranial injuries and complications during hospital stay.
METHODS
In total, 186 TBI patients aged > 18 years with minimum survival for at least 12 h admitted to the ICU at the level 1 trauma center were prospectively included in the study and divided into two groups: TBI with and without extra cranial injuries. All admitted patients were treated according to the standard institutional protocol. The PCT levels were obtained on admission, on day 2, and 5. Clinical, laboratory, diagnostic, and therapeutic data were also collected. Primary mortality is defined as death related to central nervous system (CNS) injury, while secondary mortality defined as death related to sepsis or extracranial cause.
RESULTS
Median PCT levels at admission, day 2, and day 5 in TBI patients with extracranial injuries were 3.0, 0.83, and 0.69 ng/ml. In total, primary mortality was observed in 18 (9.7%) patients, while secondary causes were attributable in 20 (12.3%) patients. Regression analysis for primarily CNS cause of mortality showed PCT cutoff level at admission more than 5.5 ng/ml carried sensitivity and specificity of 75%, but for secondary cause (sepsis) of mortality, PCT cutoff values on day 2 > 1.15 ng/ml were derived significant with sensitivity of 70% and specificity of 66%. No significant association of parameters like length of ICU stay, Glasgow outcome scale (GOS), and primary/secondary mortality with the presence of extracranial injuries in TBI patients as compared with TBI alone was noted.
CONCLUSION
This observational study demonstrates the poor correlation between PCT concentrations with outcome at days 1, 2, and 5 post-injury. The predicted relationship between PCT levels and outcome was not confirmed, and that these results do not support the prognostic utility of PCT biomarker in this population for outcome (mortality) assessment in TBI patients with or without extracranial injuries.

Identifiants

pubmed: 32533544
doi: 10.1007/s12028-020-01009-y
pii: 10.1007/s12028-020-01009-y
pmc: PMC7292243
doi:

Substances chimiques

Procalcitonin 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

182-192

Références

Crit Care. 2003 Feb;7(1):85-90
pubmed: 12617745
Dig Surg. 1998;15(3):260-5
pubmed: 9845596
Lancet. 2004 Feb 21;363(9409):600-7
pubmed: 14987884
Crit Care Med. 2006 Jul;34(7):1996-2003
pubmed: 16715031
Br J Pharmacol. 2010 Jan 1;159(2):253-64
pubmed: 20002097
Br J Anaesth. 2005 Jun;94(6):767-73
pubmed: 15849208
J Trauma. 1974 Mar;14(3):187-96
pubmed: 4814394
J Lab Clin Med. 1999 Jul;134(1):49-55
pubmed: 10402059
Am J Med Sci. 1996 Jul;312(1):12-8
pubmed: 8686724
Clin Biochem Rev. 2017 Apr;38(2):59-68
pubmed: 29332972
Anesthesiology. 2002 Jan;96(1):74-9
pubmed: 11753005
J Trauma. 2009 Jan;66(1):243-9
pubmed: 19131834
BMC Anesthesiol. 2013 Dec 15;13(1):48
pubmed: 24330775
Infect Dis Clin North Am. 1999 Jun;13(2):483-94, xi
pubmed: 10340179
J Int Med Res. 2009 Nov-Dec;37(6):1709-17
pubmed: 20146868
Intensive Care Med. 2002 Aug;28(8):1094-102
pubmed: 12185431
Physiol Res. 2000;49 Suppl 1:S57-61
pubmed: 10984072
Am J Respir Crit Care Med. 2006 Jul 1;174(1):84-93
pubmed: 16603606
Lancet. 1993 Feb 27;341(8844):515-8
pubmed: 8094770
J Intensive Care. 2017 Aug 3;5:51
pubmed: 28794881
Am J Respir Crit Care Med. 2005 Jan 1;171(1):48-53
pubmed: 15447947
Crit Care Med. 2000 Apr;28(4):977-83
pubmed: 10809269
Crit Care Med. 2000 Apr;28(4):950-7
pubmed: 10809265
Am J Respir Crit Care Med. 2008 Mar 1;177(5):498-505
pubmed: 18096708
J Emerg Trauma Shock. 2015 Jul-Sep;8(3):131-9
pubmed: 26229295
Crit Care Med. 2000 Feb;28(2):458-61
pubmed: 10708183
Intensive Care Med. 1998 Jul;24(7):680-4
pubmed: 9722037

Auteurs

Keshav Goyal (K)

Department of Neuroanaesthesiology and Critical Care, Neurosciences Centre, All India Institute of Medical Sciences, New Delhi, 7th Floor, 710, New Delhi, 110029, India. keshavgoyalster@gmail.com.

Gaurav Singh Tomar (GS)

Department of Neuroanaesthesiology and Critical Care, Neurosciences Centre, All India Institute of Medical Sciences, New Delhi, 7th Floor, 710, New Delhi, 110029, India.

Kangana Sengar (K)

Department of Lab Medicine, J.P.N. Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India.

Gyaninder Pal Singh (GP)

Department of Neuroanaesthesiology and Critical Care, Neurosciences Centre, All India Institute of Medical Sciences, New Delhi, 7th Floor, 710, New Delhi, 110029, India.

Richa Aggarwal (R)

Department of Critical Care and Intensive Care, J.P.N. Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India.

Kapil Dev Soni (KD)

Department of Critical Care and Intensive Care, J.P.N. Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India.

Purva Mathur (P)

Department of Microbiology, J.P.N. Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi, India.

Shweta Kedia (S)

Department of Neurosurgery, Neurosciences Center, All India Institute of Medical Sciences, New Delhi, India.

Hemanshu Prabhakar (H)

Department of Neuroanaesthesiology and Critical Care, Neurosciences Centre, All India Institute of Medical Sciences, New Delhi, 7th Floor, 710, New Delhi, 110029, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH